JPRN-UMIN000030545招募中2 期
Afatinib plus Bevacizumab Combination after osimertinib failure for aDvanced EGFR-mutant non-small cell lung cancer: a multicenter prospective single arm phase II study (ABCD-study) - Afatinib plus Bevacizumab after Osimertinib failure
Hanshin Oncology Group0 个研究点目标入组 26 人开始时间: 2018年1月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Interstitial lung disease or pulmonary fibrosis 2) Symptomatic central nervous system metastases 3) History of severe allergic reaction to drugs 4) Severe infection or comorbidities 5) Massive or uncontrolled pleural, abdominal, or cardiac effusion 6) Clinically significant arythmia, angina, or heart failure 7) Uncontrolled hypertension 8) Uncntrolled diabetes 9) Active double cancers 10) Hitologically dominant of squanous carcinoma 11) Severe phycological disease 12) Massive hemoptysis 13) Gastrointestinal perfolation within 1 year 14) Incurable bone fracture 15) Planning major surgery during trial 16) Bleeding tendency 17) Uncontrolled thrombosis 18) Receipt of EGFR-TKIs other than Osimertinib or immunotherapy 19) Pregnancy 20) Patients whom doctos in charge judge unproper
研究者
相似试验
已完成
2 期
Afatinib Plus Bevacizumab After Osimertinib Failure(ABCD-study/ HANSHIN Oncology Group 0217 trial))Lung cancerung canerJPRN-jRCTs051180205Hata Akito28
已完成
不适用
A phase I study Afatinib in Combination of Osimertinib in patients with Relapsed Non-Small Cell Lung Cancer after failure of prior Osimertinibon-small cell lung cancerJPRN-UMIN000031501iigata Cancer Center Hospital20
已完成
2 期
Osimertinib combined bevacizumab in untreated epidermal growth factor receptor mutaeted non-small-cell lung cancer patients with malignant pleural and/or pericardial effusion -phase II trialadvanced/recurrent non-small cell lung cancer (NSCLC)JPRN-UMIN000028071Clinical Research Support Center Kyushu31
已完成
1 期
A phase I study of osimertinib with bevacizumab and randomized phase II study of osimertinib with or without bevacizumab in EGFR mutated, T790M positive patients who had progressed EGFR-TKIs. (WJOG8715L)ung CancerJPRN-UMIN000023761West Japan Oncology Group87
已完成
2 期
Afatinib Plus Bevacizumab After Acquired Resistance to EGFR-TKI in EGFR-mutant NSCLCon-small cell lung cancerJPRN-UMIN000014710Foundation for Biomedical Research and Innovation32